September 4, 2008 - Cancer patients in Europe, and possibly worldwide, may face a longer wait for diagnostic tests and treatments as a nuclear reactor in the Netherlands that supplies medical isotopes extended its shutdown for potential safety reasons.

Nuclear Research and Consultancy Group, which operates the reactor in Petten, in northwestern Netherlands, said Wednesday it would not start up the reactor again before the end of October.

About 15 to 20 percent of Canada's medical isotopes come from overseas, including the Petten facility, according to Health Canada.

"The consequences of this further delay will have an impact on the medical isotope market," the Dutch company said in a statement.

"NRG will not produce any medical isotopes in the months September and October (until 25th of October). We have already informed our customers about the situation. We are assisting in the search for alternative supply routes."

NRG stopped activity at the reactor after air bubbles were discovered in its cooling system. The company has said there is no danger to the public or the environment.

The reactor is the second-biggest producer of medical isotopes worldwide after Atomic Energy of Canada Ltd.'s facility at Chalk River, ON. The Dutch reactor produces the majority of the world supply of isotopes of the element technetium, which give off radiation used in medical imaging and disease treatments.

Technetium-99m is used in 80 percent of diagnostic imaging that uses nuclear medicine technology, including imaging of the heart, kidney and brain. NRG-made isotopes account for seven million diagnostic tests per year in Europe and eight million per year in the U.S., according to the company.

Last week, AECL said that, given the problems in the Netherlands, the nuclear reactor at Chalk River, ON, could ramp up to meet Canada's demand for medical isotopes if required.

But MDS Nordion, a Canadian company that buys isotopes from AECL and sells them to pharmaceutical manufacturers, said: "MDS Nordion does not determine the allocation of medical isotopes to specific end users," such as hospitals in Canada or worldwide.

"We are concerned there is currently no reliable, long-term isotope supply solution to meet this growing demand. As a result, there is risk of isotope shortages recurring," MDS Nordion said in a statement last week.

In December 2007, unexpected problems during routine maintenance at Chalk River forced the reactor to be taken offline, causing a shortage of medical isotopes worldwide.

Source: cbcnews.ca
For more information: www.cbc.ca


Related Content

News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Contrast Media Injectors | By Christine Book

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
News | Interventional Radiology

November 3, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

Time November 03, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

October 17, 2023 — Halo Precision Diagnostics, a leader in early disease detection using precision diagnostics, today ...

Time October 17, 2023
arrow
News | Ultrasound Imaging

September 15, 2023 — Contrast enhanced ultrasound (CEUS) is underutilized in the United States, and reduced access to ...

Time September 15, 2023
arrow
News | Prostate Cancer

July 28, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 28, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

July 27, 2023 — Scientists have found a new use for copper in magnetic resonance imaging (MRI) contrast agent design ...

Time July 27, 2023
arrow
News | Contrast Media

July 25, 2023 — Bracco Imaging has issued a statement on new results published in the journal Radiology which found that ...

Time July 25, 2023
arrow
News | Contrast Media

June 20, 2023 — Ascelia Pharma presented data from its Orviglance Hepatic Impairment study during the European Society ...

Time June 20, 2023
arrow
Subscribe Now